X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (78) 78
humans (75) 75
hematology (62) 62
life sciences (56) 56
cancer (46) 46
male (45) 45
female (44) 44
middle aged (41) 41
aged (40) 40
oncology (37) 37
rituximab (31) 31
immunology (29) 29
leukemia, lymphocytic, chronic, b-cell - drug therapy (27) 27
adult (24) 24
aged, 80 and over (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (22) 22
chronic lymphocytic leukemia (21) 21
treatment outcome (21) 21
chemotherapy (19) 19
care and treatment (17) 17
abridged index medicus (16) 16
cll (16) 16
human health and pathology (16) 16
leukemia (16) 16
chronic lymphocytic-leukemia (15) 15
lymphomas (15) 15
retrospective studies (15) 15
cyclophosphamide (14) 14
lymphoma (14) 14
survival (14) 14
therapy (14) 14
disease-free survival (12) 12
mutation (12) 12
patients (12) 12
antineoplastic agents - therapeutic use (11) 11
follicular lymphoma (11) 11
leukemia, lymphocytic, chronic, b-cell - genetics (11) 11
leukemia, lymphocytic, chronic, b-cell - pathology (11) 11
prognosis (11) 11
activation (10) 10
antibodies, monoclonal, murine-derived - administration & dosage (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
chronic lymphatic leukemia (10) 10
expression (10) 10
fludarabine (10) 10
immunotherapy (10) 10
leukemia, lymphocytic, chronic, b-cell - mortality (10) 10
open-label (10) 10
research (10) 10
hematology, oncology and palliative medicine (9) 9
hemic and lymphatic diseases (9) 9
protein kinase inhibitors - therapeutic use (9) 9
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
b-cell lymphoma (8) 8
cyclophosphamide - administration & dosage (8) 8
ibrutinib (8) 8
immune system diseases (8) 8
elderly (7) 7
human necessities (7) 7
hygiene (7) 7
medical or veterinary science (7) 7
salvage therapy (7) 7
time factors (7) 7
transplantation (7) 7
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (6) 6
[sdv]life sciences [q-bio] (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
chronic lymphocytic leukaemia (6) 6
follow-up studies (6) 6
kaplan-meier estimate (6) 6
leukemia, lymphocytic, chronic, b-cell - complications (6) 6
lymphatic leukemia (6) 6
non-hodgkins-lymphoma (6) 6
phosphorylation (6) 6
preparations for medical, dental, or toilet purposes (6) 6
pyrazoles - therapeutic use (6) 6
pyrimidines - therapeutic use (6) 6
recurrence (6) 6
risk factors (6) 6
survival analysis (6) 6
testing (6) 6
vidarabine - analogs & derivatives (6) 6
[sdv.can]life sciences [q-bio]/cancer (5) 5
aged patients (5) 5
analysis (5) 5
animals (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antibodies, monoclonal, murine-derived - adverse effects (5) 5
antineoplastic agents - pharmacology (5) 5
apoptosis (5) 5
b-cells (5) 5
bendamustine (5) 5
chemistry (5) 5
cyclophosphamide - adverse effects (5) 5
dexamethasone - administration & dosage (5) 5
diagnosis (5) 5
drug therapy (5) 5
elderly-patients (5) 5
france - epidemiology (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Haematology, ISSN 2352-3026, 07/2019, Volume 6, Issue 7, pp. e343 - e344
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1741 - 1741
A 60-year-old man presented with a 4-week history of progressive skin lesions. For the past 6 years, he had been treated for CLL with successive administration... 
MEDICINE, GENERAL & INTERNAL | Antigens | Skin diseases | Chronic lymphatic leukemia | Cryptococcosis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2011, Volume 29, Issue 31, pp. 4079 - 4087
Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively... 
MOLECULAR SUBTYPES | SURVIVAL | ONCOLOGY | RISK STRATIFICATION | R-CHOP | RITUXIMAB | NON-HODGKINS-LYMPHOMAS | CLASSIFICATION | TISSUE MICROARRAY | ELDERLY-PATIENTS | EXPRESSION | Immunohistochemistry | Multivariate Analysis | Predictive Value of Tests | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Gene Expression Regulation, Neoplastic | Male | Gene Expression Profiling | Antigens, CD20 - blood | Cisplatin - administration & dosage | Multicenter Studies as Topic | Microarray Analysis | Lymphoma, Large B-Cell, Diffuse - chemistry | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Neoplasm Proteins - genetics | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Biomarkers, Tumor - analysis | Risk Factors | Proportional Hazards Models | Carboplatin - administration & dosage | Rituximab | Etoposide - administration & dosage | In Situ Hybridization, Fluorescence | Germinal Center - pathology | Cytarabine - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm, Residual - drug therapy | Neoplasm Proteins - analysis | Aged | Biomarkers, Tumor - genetics | Salvage Therapy - methods | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2302 - 2302
Abstract Introduction: Idelalisib (IDELA), the first PI3K delta inhibitor, is indicated in Europe in combination with rituximab (R) or ofatumumab for the... 
Journal Article
Journal Article
BMC CANCER, ISSN 1471-2407, 08/2019, Volume 19, Issue 1, pp. 809 - 11
Background Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker... 
INDEPENDENT PREDICTOR | CLL | FREE SURVIVAL | Chronic lymphocytic Leukaemia | Minimal residual disease | IBRUTINIB | CD4 T-cells | OPEN-LABEL | PREVIOUSLY UNTREATED PATIENTS | Immunosuppression | PHASE-II TRIAL | THERAPY | ONCOLOGY | Chemo-immunotherapy | PROGRESSION-FREE | Prognosis | Follow-Up Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | CD4-Positive T-Lymphocytes - pathology | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Neoplasm, Residual | Rituximab - therapeutic use | Female | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Rituximab - adverse effects | Vidarabine - adverse effects | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Lymphocyte Count | Immunoglobulin Variable Region - genetics | Immunosuppressive Agents - adverse effects | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Mutation | CD4-Positive T-Lymphocytes - drug effects | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Complications and side effects | Chronic lymphocytic leukemia | Cyclophosphamide | CD4 lymphocytes | Physiological aspects | Genetic aspects | Dosage and administration | Research | Drug therapy | Life Sciences | Human health and pathology | Immunology | Hematology | Cancer
Journal Article
Leukemia, ISSN 0887-6924, 2019, Volume 33, Issue 11, pp. 2654 - 2661
A staging system was developed a decade ago for patients with Waldenström’s macroglobulinemia (WM), however, since then WM treatments have changed. A revised... 
Medical prognosis | Rituximab | Risk | Serum albumin | Patients | b2-microglobulin | Macroglobulinemia
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2017, Volume 4, Issue 3, pp. e114 - e126
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 10/2016, Volume 11, Issue 10, p. e0162965
Hepatitis C virus (HCV) infection is associated with lymphoproliferative disorders and B-cell non-Hodgkin lymphomas (B-NHLs). Evaluation of the efficacy and... 
VIRUS-INFECTION | THERAPY | MULTIDISCIPLINARY SCIENCES | MARGINAL ZONE LYMPHOMA | HEPATITIS-C | CRYOGLOBULINEMIA VASCULITIS | MIXED CRYOGLOBULINEMIA | Lymphoma, B-Cell - complications | Recombinant Proteins - therapeutic use | Multivariate Analysis | Hepatitis C - drug therapy | Humans | Lymphoma, B-Cell - diagnosis | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Polyethylene Glycols - therapeutic use | Lymphoma, B-Cell, Marginal Zone - complications | Female | Hepatitis C - complications | RNA, Viral - metabolism | Drug Therapy, Combination | Odds Ratio | Protease Inhibitors - therapeutic use | Hepacivirus - isolation & purification | Enzyme-Linked Immunosorbent Assay | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Proportional Hazards Models | Genotype | Lymphoma, Large B-Cell, Diffuse - complications | Survival Rate | Treatment Outcome | Hepatitis C - mortality | Hepatitis C - virology | Aged | Surveys | Infection | Care and treatment | Protease inhibitors | Proteases | Biological products industry | Interferon | Non-Hodgkin's lymphomas | Biological response modifiers | Comparative analysis | Hepatitis C virus | Health aspects | Therapy | Liver | Viruses | Infections | Multivariate analysis | Drug development | Ribavirin | Hepatitis | α-Interferon | Lymphocytes | Hepatology | Safety | Public health | Evaluation | Antiviral agents | Internal medicine | Hematology | Immunoproliferative diseases | Proteinase inhibitors | Patients | Lymphoma | Medicine | Studies | Chemotherapy | Lymphocytes B | Lymphomas | Hepatitis C | B-cell lymphoma | Life Sciences | Human health and pathology
Journal Article
Annals of Hematology, ISSN 0939-5555, 4/2019, Volume 98, Issue 4, pp. 931 - 939
Delivering of > 80% planned relative dose intensity (RDI) of fludarabine-cyclophosphamide-rituximab (FCR) is key to benefit from longer progression free... 
Oncology nurse | CLL | Immunochemotherapy | Medicine & Public Health | Hematology | Oncology | Survivorship | Relative dose intensity | CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | OPEN-LABEL | PHASE-3 | FLUDARABINE | B-CELL LYMPHOMA | THERAPY | FCR | NEUTROPENIA | RITUXIMAB | HEMATOLOGY | Oncology, Experimental | Research | Cancer | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 1955 - 1955
Abstract Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western Countries. This pathology is characterized by an accumulation of monoclonal,... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article